Evidence that elastase is the TNF-R75 shedding enzyme in resting human polymorphonuclear leukocytes  by Gasparini, Chiara et al.
Evidence that elastase is the TNF-R75 shedding enzyme in
resting human polymorphonuclear leukocytes
Chiara Gasparini, Renzo Menegazzi, Pierluigi Patriarca, Pietro Dri
Department of Physiology and Pathology, University of Trieste, Via A. Fleming 22, Trieste, Italy
Received 12 May 2003; revised 14 July 2003; accepted 16 July 2003
First published online 25 September 2003
Edited by Beat Imhof
Abstract We previously showed that a metalloprotease and a
serine protease mediate shedding of the TNF-R75 (75-kDa tu-
mor necrosis factor receptor) in neutrophils. Here we show that
elastase is the TNF-R75 solubilizing serine protease. Release of
the TNF-R75 by resting cells was almost totally inhibited by the
serine protease inhibitor diisopropyl£uorophosphate (DFP), by
two synthetic, chemically unrelated, elastase-speci¢c inhibitors
and by K1-protease inhibitor. Release after TNF or FMLP
(N-formyl-L-methionyl-L-leucyl-L-phenylalanine) stimulation was
blocked by DFP and a metalloprotease inhibitor used in combi-
nation. Supernatants from resting neutrophils contained a 28-
kDa fragment of the receptor, compatible with that generated
by elastase, whose appearance was inhibited by DFP. Upon
FMLP stimulation, the release of 28-kDa and 40-kDa frag-
ments was observed, which was inhibited by DFP and a metal-
loprotease inhibitor, respectively. We conclude that elastase is
the TNF-R75 sheddase of resting neutrophils and that it con-
tributes to shedding of this receptor in stimulated cells.
3 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Tumor necrosis factor (TNF) is a cytokine produced by a
number of cells, including macrophages, lymphocytes and nat-
ural killer cells [1]. Based on the diverse biologic activities it
exerts, TNF is generally considered a potent mediator of host
response to injury, in£ammation, immunity and repair [2].
Cellular responses to TNF are initiated following interaction
with two receptors, namely the 55-kDa receptor (TNF-R55)
and the 75-kDa receptor (TNF-R75), which are expressed on
all nucleated cells. Neutrophils, the most abundant cells of the
acute in£ammatory reaction, express surface TNF receptors
and likewise respond to the cytokine by activating several cell
functions, including adherence [3,4], production of superoxide
anion and hydrogen peroxide [4^7], e¥ux of chloride ions [8],
and solubilization of TNF receptors themselves [7,9]. Solubi-
lization, or shedding, is an important mechanism for control
of the expression of TNF receptors. In neutrophils, the solu-
bilization of TNF receptors can be induced by agonists other
than TNF, including FMLP (N-formyl-L-methionyl-L-leucyl-
L-phenylalanine), C5a, GM-CSF or PMA [7,9^12]. The down-
regulation of TNF receptors causes functional deactivation of
neutrophils to TNF and appears to be a mechanism of self-
protection against excessive stimulation by the cytokine
[11,13,14]. On the other hand, by competing for TNF with
membrane receptors, solubilized receptors may contribute to
dampening pro-in£ammatory and potentially toxic e¡ects in
conditions such as rheumatoid arthritis, Crohn’s disease, mul-
tiple sclerosis or other pathologies in which TNF has been
shown to play an important role [15^18].
Based on experiments with protease inhibitors, it has been
shown in di¡erent cell types that both metalloproteases and
serine proteases are involved in the release of TNF receptors
[19,20]. We have also recently shown that the TNF-induced
shedding of TNF receptors from polymorphonuclear leuko-
cytes (PMN) involves metalloproteases and serine proteases
[9]. More speci¢cally, we have shown that release of TNF-
R55 was almost completely inhibited by KB8301, a hydrox-
amate-based metalloprotease inhibitor, while the release of
TNF-R75 was only partially a¡ected by this inhibitor. The
solubilization of this latter receptor, but not TNF-R55, was
also inhibited to some extent by the broad-spectrum serine
protease inhibitor diisopropyl£uorophosphate (DFP) [9]. In
this study, we identify the DFP-sensitive protease involved
in shedding of TNF-R75. Based on the results of studies
with protease-speci¢c inhibitors and by molecular analysis
of the solubilized receptor fragments, it can be suggested
that elastase is the TNF-R75 sheddase in resting neutrophils.
In stimulated cells, both elastase and a metalloprotease con-
tribute to the shedding of TNF-R75.
2. Materials and methods
2.1. Reagents
Bovine serum albumin (BSA) fraction V, FMLP, porcine pancreatic
elastase type VI, BCIP (5-bromo-4-chloro-3-indolyl phosphate), NBT
(nitro blue tetrazolium), protein G solubilized and cross-linked on
agarose beads were obtained from Sigma (St. Louis, MO, USA);
Percoll was obtained from Pharmacia (Uppsala, Sweden); strepta-
vidin-AP conjugate was from BIOSPA (Milan, Italy). Pure, recombi-
nant human TNF, expressed in Escherichia coli was obtained from
Bissendorf Biochemicals (Hannover, Germany). Immunoassays for
human TNF-R55 and TNF-R75 were performed using ELISA kits
obtained from RpD Systems (Minneapolis, MN, USA). All solutions
were made in endotoxin-free water for clinical use.
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2.2. Protease inhibitors
The K1-protease inhibitor was from Sigma, DFP was purchased from
Acros Organics, NJ, USA; [4-(N-hydroxyamino)-2R-isobutyl-3S-
methylsuccinyl]-L-3-(5,6,7,8-tetrahydro-1-naphthyl)alanine-N-methyl-
amide (KB8301) [21] was kindly provided by K. Yoshino, Kanebo
Ltd., Osaka, Japan; ZM200,355 (or ICI200,355) [22] was provided
by Zeneca Pharmaceuticals, Cheshire, UK; L658758 [23] was from
Merck, Sharp and Dohme Research Laboratory, NJ, USA.
2.3. Antibodies
M80, a rabbit anti-human TNF-R75 polyclonal antibody [24], was
a generous gift of Dr. P. Scheurich (University of Stuttgart, Stuttgart,
Germany); utr-1 (subclass IgG1), a mouse anti-human TNF-R75
mAb [25], was kindly provided by Dr. M. Brockhaus (Ho¡man-
LaRoche, Basel, Switzerland); biotinylated goat anti-mouse antibody
was from BIOSPA (Milan, Italy).
2.4. Neutrophil isolation
Blood was drawn from healthy volunteers and anticoagulated with
4 mM EDTA. Neutrophils were isolated according to a single-step
separation procedure as previously described [26] with an adaptation
of the method to larger blood volumes, by layering 15 ml of blood
over the two-step gradient (15 ml 75% isotonic Percoll, 15 ml 62%
isotonic Percoll) formed in 50 ml conical test tubes. The cell popula-
tion contained 95^98% neutrophils, 2^4% eosinophils, and 1^2%
mononuclear cells. The entire procedure was carried out in the ab-
sence of divalent cations to avoid neutrophil aggregation and activa-
tion. Before starting each experiment, the cell suspensions and the
incubation medium were supplemented with 1 mM CaCl2 and 1 mM
MgCl2 (HBS^BSA).
2.5. Soluble receptor assay
PMN (5U106/ml in HBS-BSA), prewarmed to 37‡C, were incuba-
ted without and with protease inhibitors for 3 min and then for an
additional 20 min with 2.5 ng/ml TNF or 1037 M FMLP. After cool-
ing on ice and centrifugation, the supernatants were collected and
used for assays. Soluble receptors were measured by means of two
ELISA kits speci¢c for TNF-R55 or TNF-R75. The kits utilized 96-
well microplates coated with receptor-speci¢c murine monoclonal
antibodies. TNF-R-speci¢c polyclonal antibodies conjugated to horse-
radish peroxidase were used to detect receptor binding to the mono-
clonal antibodies. The sensitivity of the ELISAs is 6 3 and 6 1 pg/ml
for TNF-R55 and TNF-R75, respectively. According to the manufac-
turers, in these immunoassays TNF does not show any signi¢cant
cross-reactivity and only a low interference (with TNF-K at 5 ng/ml,
the observed value was decreased by 10%).
2.6. Immunoprecipitation, SDS^PAGE, and Western blot analysis
PMN (25^30U106 cells in 1 ml HBS-BSA) were incubated with
protease inhibitors for 3 min at 37‡C and then in the absence (60
min) or in the presence (20 min) of FMLP (1037M) or elastase (20
Wg/ml). The PMN suspensions were then cooled on ice, centrifuged,
and the supernatants collected. TNF receptors were also extracted
from intact PMN. In these experiments, PMN (5U106) were centri-
fuged and resuspended in lysis bu¡er (0.5% sodium deoxycholate, 1%
Triton, 0.1% SDS, 1 mM 1,10-Phenantroline, 2.5 mM Na4EDTA,
2 mM iodoacetic acid, 2.8 mM DFP in HBS) and incubated at 4‡C
for 20 min. After centrifugation at 12 000Ug for 5 min supernatants
were collected.
Supernatants were precleared by incubation with protein G Sephar-
ose at 4‡C for 1 h under continuous rotation. After centrifugation,
TNF-R75 was immunoprecipitated from the supernatants after over-
night incubation at 4‡C with antibody M80 (6 Wg/condition) and
protein G Sepharose. After washing three times with 0.4 M NaCl,
0.5% DOC, 0.5% Triton, 0.05% SDS in BSA-free HBS, the protein
G Sepharose pellets were suspended in sample bu¡er, boiled for 3 min,
and subjected to SDS^PAGE on a 10% gel under non-reducing con-
ditions, according to the method of Laemmli [27]. After electro-
phoresis, the proteins were transferred to a nitrocellulose membrane
by Western blotting according to the method described by Towbin
[28]. The nitrocellulose membrane was incubated overnight at 4‡C
with blocking bu¡er (25 mM Tris^HCl, 0.9% NaCl, pH 7.4 containing
5% non-fat dry milk and 0.02% Tween 20) and then with 1 Wg/ml
mAb utr-1 in blocking bu¡er at room temperature under agitation for
45 min. From this step on, dry milk was omitted from the incubation
bu¡er. The membrane was washed twice and incubated with a bio-
tinylated secondary antibody for 45 min. After two additional wash-
ings and incubation with streptavidin conjugated with alkaline phos-
phatase for 30 min, the bound alkaline phosphatase was detected by
incubation with NBT and BCIP.
3. Results and discussion
3.1. A serine protease is involved in shedding of TNF-R75 from
PMN
While studying the e¡ect of a panel of protease inhibitors
on TNF-induced shedding of its receptors in PMN, it was
found that the release of TNF-R55 was almost completely
inhibited by the hydroxamic acid-based metalloprotease inhib-
itor KB8301 (90.7 R 9.1%). The release of TNF-R75 was only
partially inhibited by this compound (51.0 R 8.1%) (Fig. 1).
The characteristics of the KB8301-sensitive metalloprotease
responsible for the TNF-induced release of TNF-R55 and
TNF-R75 have recently been de¢ned [9]. Fig. 1 also shows
that TNF-induced shedding of TNF-R55 was una¡ected by
DFP, a broad-spectrum serine protease inhibitor, while shed-
ding of TNF-R75 was slightly but signi¢cantly inhibited
(17.4 R 5.2%) by this compound. KB8301 and DFP in combi-
nation almost totally suppressed release of TNF-R75, indicat-
ing that metalloproteases and serine proteases completely ac-
count for the TNF-induced shedding of this receptor. Fig. 2
shows that results similar to those obtained with TNF are
observed when FMLP is used as a stimulus, indicating that
a common biochemical mechanism is involved in shedding of
TNF-Rs, irrespective of the inducing agent. The observation
that the inhibitory e¡ect of the two compounds in combina-
tion is larger than the sum of either compound alone suggests
that a synergistic cooperation between serine proteases and
metalloproteases might be involved in the stimulated shedding
of TNF-R75. Cooperation between these proteases has also
been suggested for the PMA-induced shedding of TNF recep-
tors in myeloid cell lines [20]. Based on previous observations,
showing that resting PMN release substantial amounts of
TNF-R75 but negligible amounts of TNF-R55 [9], we tested
the e¡ect of KB8301 and DFP on the resting release of both
receptors. Table 1 shows that in contrast to the release of
Fig. 1. E¡ect of the metalloprotease inhibitor KB8301 and the ser-
ine protease inhibitor DFP on the TNF-induced shedding of TNF
receptors in human PMN. PMN (5U106/ml in HBS-BSA) were pre-
incubated at 37‡C for 3 min with or without 5 Wg/ml KB8301 and/
or 1 mM DFP and then for 20 min with 2.5 ng/ml TNF. After
cooling and centrifugation, the solubilized receptors were measured
in the supernatants as described in Section 2. The results are means
of four experiments. Bars indicate standard deviations. * and **,
statistical di¡erences compared with TNF-treated cells (P6 0.05 and
P6 0.01, respectively).
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TNF-R55 (strong inhibition by KB8301, insensitivity to
DFP), release of TNF-R75 was una¡ected by KB8301 and
almost totally inhibited by DFP. Thus, a serine protease ap-
pears to be responsible for the resting release of TNF-R75.
3.2. Elastase is the TNF-R75-releasing serine protease
It has been shown that azurophil granule-enriched fractions
from either resting or FMLP-activated PMN were potent
down-regulators of TNF receptors [29]. The azurophil gran-
ule-associated TNF-receptor releasing activity responsible for
this down-modulation, a¡ecting almost exclusively TNF-R75,
was tentatively identi¢ed as elastase on the basis of the fact
that it was inhibited by DFP and elastase inhibitors and was
reproduced by exogenously added puri¢ed elastase [29].
Curiously, however, the elastase-dependent TNF-R75 cleav-
ing activity of azurophil granules was considered distinct from
the sheddase operative in intact stimulated PMN and re-
garded as an additional mechanism for the control of cellular
responses to TNF at sites of in£ammation, secondary to azur-
ophilic granule exocytosis [29]. This latter observation might
appear paradoxical if one takes into consideration that human
PMN contain abundant amounts of elastase [30,31]. More-
over, this protease is expressed in an active form on the cell
surface and its expression is increased in stimulated cells ([32^
35] and our data not shown). We therefore hypothesized that
elastase is the serine protease responsible for TNF-R75 shed-
ding from resting PMN and also for the DFP-inhibitable
fraction of the receptor released from TNF or FMLP-stimu-
lated PMN. We tested this possibility using the macromolec-
ular physiological inhibitor of elastase, K1-protease inhibitor,
and two chemically unrelated elastase-speci¢c synthetic inhib-
itors. One of them, compound ZM200,355, belongs to a fam-
ily of tri£uoromethylketone derivatives [22,36] and has been
shown to be highly selective for neutrophil elastase with very
little or no inhibitory activity, even at relatively high concen-
trations, against other types of serine proteases (e.g. cathep-
sins), cysteine proteases or MMPs [37]. The other, compound
L-658758, belongs to a family of cephalosporin-based L lac-
tam inhibitors shown to be excellent inhibitors of leukocyte
elastase with no signi¢cant activity against serine proteinases
such as cathepsin G and tripsin [23,38].
Both compounds were used at concentrations reported to
inhibit elastase in isolated neutrophils by more than 80%
[36,39]. Fig. 3 shows that ZM200,355 and L-658758 com-
Fig. 2. E¡ect of the metalloprotease inhibitor KB8301 and the ser-
ine protease inhibitor DFP on the FMLP-induced shedding of TNF
receptors in human PMN. PMN (5U106/ml in HBS-BSA) were pre-
incubated at 37‡C for 3 min with or without 5 Wg/ml KB8301 and/
or 1 mM DFP and then for 20 min with 5U1038 M FMLP. After
cooling and centrifugation, the solubilized receptors were measured
in the supernatants as described in Section 2. The results are means
of three experiments. Bars indicate standard deviations. * and **,
statistical di¡erences compared with FMLP-treated cells (P6 0.05
and P6 0.01, respectively).
Table 1
E¡ect of KB8301 and DFP on the release of TNF receptors from
resting human PMNa
TNF-R55
(pg/106 cells)b
TNF-R75
(pg/106 cells)b
Resting 2.26R 0.7 16.90R5.9
+5 WM KB8301 0.26R 0.2* 14.91R4.4
+1 mM DFP 1.56R 0.6 0.22R0.7*
*P6 0.01 vs. resting PMN.
aPMN (5U106/ml) after temperature equilibration for 10 min at
37‡C were incubated for 20 min under constant agitation. After
cooling at 0‡C, cells were centrifuged at 400Ug for 7 min, and the
supernatants used for soluble receptors assay, as described in Sec-
tion 2.
bThe results are the means RS.D. of ¢ve experiments.
Fig. 3. E¡ect of the elastase-speci¢c synthetic inhibitors L658758
and ZM200,355 and the physiologic elastase inhibitor K1-PI on the
release of TNF receptors from resting (A) and from TNF- (B) or
FMLP- (C) treated PMN. PMN (5U106/ml in HBS-BSA) were pre-
incubated at 37‡C for 3 min with or without 25 Wg/ml L658758, 20
WM ZM200,355 or 20 Wg/ml K1-PI, and then for 20 min without
(resting) and with 2.5 ng/ml TNF or 5U1038 M FMLP. After cool-
ing and centrifugation, the solubilized receptors were measured in
the supernatants as described in Section 2. The results are the
means of three to four experiments with L658758 and ZM200,355
and of two experiments with K1-PI. Bars indicate standard devia-
tions. * and **, statistical di¡erences compared with cells in the ab-
sence of inhibitors (P6 0.05 and P6 0.01, respectively).
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pletely inhibit the release of TNF-R75 from resting cells and,
partially, the release from stimulated cells, without a¡ecting
the release of TNF-R55, as expected. K1-Protease inhibitor
also inhibited the release of the receptor, although its e¡ect
was less pronounced than that induced by the synthetic inhib-
itors. This latter ¢nding would not be unexpected if indeed a
membrane-bound elastase is involved in shedding. In fact, it
has been shown that, contrary to soluble elastase, membrane-
associated elastase is less e¡ectively inhibited by macromolec-
ular inhibitors such as K1-protease inhibitor [32]. Taken alto-
gether, these results suggest that elastase, in a membrane-as-
sociated form, is involved in the cleavage of TNF-R75. The
membrane localization of the enzyme is additionally sup-
ported by the recent demonstration that supernatants from
PMN stimulated with FMLP are devoid of TNF receptor-
solubilizing activity [9].
3.3. Evidence for metalloprotease and elastase involvement in
shedding of TNF-R75 by molecular analysis of the
solubilized fragments of the receptor
It has previously been shown that cleavage of TNF-R75 by
elastase generates a fragment of approximately 32 kDa,
whereas a fragment of about 42 kDa is formed after cleavage
by the metalloprotease [29]. To further con¢rm the involve-
ment of a metalloprotease and elastase in shedding of TNF-
R75, we determined whether fragments of the receptor with a
molecular weight compatible with those generated by the two
proteases were present in supernatants from resting and
stimulated PMN.
Fig. 4 shows that supernatants from resting PMN after
incubation for 60 min exhibited a band of about 28 kDa
(lane 1). An incubation time of 60 min, instead of 20 min
(the incubation time used in other experiments), was chosen
with resting PMN since after 20 min of incubation no bands were detected in the region encompassing the molecular
weights of the soluble fragments of TNF-R75 (data not
shown). In the supernatants from PMN incubated with
DFP, the 28-kDa band was not detected, but rather a new
band of about 40 kDa became visible (lane 2). The 28-kDa
band was una¡ected by PMN incubation with the metallopro-
tease inhibitor KB8301 (lane 3). Thus, resting PMN release in
a DFP-inhibitable manner a fragment of the TNF-R75 with a
molecular weight (28 kDa) compatible with the molecular
weight of the fragment generated by elastase [29]. The 40-
kDa band observed in the supernatants from DFP-treated
PMN may represent the result of some degree of metallopro-
tease activity that becomes apparent after elastase inhibition
at incubation times longer than 20 min, even in resting PMN.
After incubation with FMLP (Fig. 5), two bands of 28 and
40 kDa were observed (lane 1), although the latter band was
not evident in all experiments. DFP (lane 2), KB8301 (lane 3),
or in combination (lane 4) prevented the appearance of the
28-kDa band, the 40-kDa band or both bands, respectively.
Fig. 5 also shows that in the supernatants from PMN incu-
bated with exogenously added elastase, two bands of similar
molecular weight were present: one 28-kDa band that may be
the counterpart of the DFP-inhibitable band observed in
supernatants from resting and FMLP-treated PMN and the
other having a mass of 26.5 kDa. This latter band may be the
product of receptor cleavage at an additional site by porcine
pancreatic elastase (the enzyme used in these experiments),
which has been shown to slightly di¡er in amino acid speci-
¢city from human leukocyte elastase [40].
Fig. 4. Western blot analysis of TNF-R75 fragments released by
resting PMN. PMN (25^30U106/ml in HBS-BSA) were incubated in
the absence (lane 1) or presence of 1 mM DFP or of 7.5 WM
KB8301 (lane 3) for 60 min at 37‡C. After cooling on ice and cen-
trifugation, the supernatants were collected and soluble TNF-R75
fragments, after immunoprecipitation, were analyzed by immuno-
blotting as described in Section 2. Lane 4: mock immunoprecipitate
carried out with the incubation medium. Lane 5: immunoprecipitate
from a whole-cell lysate where the 75-kDa broad band of the intact
receptor is apparent.
Fig. 5. Western blot analysis of TNF-R75 fragments released by
PMN after FMLP stimulation or after elastase treatment. PMN
(25^30U106/ml in HBS-BSA) after preincubation for 3 min with
1 mM DFP (lanes 2 and 6), 7.5 WM KB8301 (lane 3), both inhibi-
tors (lane 4) or without addition (lanes 1 and 5) were incubated
with 1037 M FMLP (lanes 1^4) or 20 Wg/ml elastase (lanes 5 and 6)
for 20 min at 37‡C. After cooling on ice and centrifugation, the
supernatants were collected and soluble TNF-R75 fragments, after
immunoprecipitation, were analyzed by immunoblotting as described
in Section 2. Lane 7: mock immunoprecipitate carried out with the
incubation medium. Lane 8: immunoprecipitate from a whole-cell
lysate where the 75-kDa broad band of the intact receptor is appar-
ent.
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In conclusion, the results of this study demonstrate that
elastase, in addition to the previously described metallopro-
tease [9], is involved in shedding of TNF-R75 from human
PMN. In particular, a membrane-bound form of the enzyme
appears to participate in this process and to entirely account
for receptor release in resting PMN. In stimulated PMN, a
considerable fraction of receptor release is still accounted for
by elastase, even though in quantitative terms most is due to
the activity of a metalloprotease. Neutrophil elastase therefore
appears to play a two-fold role in shedding of TNF-R-75. It
acts in an autocrine manner in intact resting or stimulated
PMN, as shown in the present report, and, after its release,
acts in a paracrine manner, both on PMN and on other cell
types present at in£ammatory sites, as previously suggested
[29]. Only a limited number of cell functions have been dem-
onstrated to be mediated by TNF-R75. In PMN, in particu-
lar, this receptor has been demonstrated to cooperate with
TNF-R55, the signaling receptor, for optimal responses to
TNF ([26] and references therein). Therefore, the shedding
activity of elastase may be regarded, on the one hand, as a
mechanism wherein TNF-binding proteins in the form of
soluble receptors are made available that subsequently partic-
ipate in the modulation of the pathophysiologic e¡ects of
TNF and, on the other, as a means to dampen down TNF-
R55-mediated responses of PMN to TNF, by decreasing ex-
pression of TNF-R75.
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